Stem Cell Advocates and Critics Push Back on FDA Guidelines – Scientific American
Scientific American |
Stem Cell Advocates and Critics Push Back on FDA Guidelines
Scientific American “It is possible that after these public meetings the FDA may step up its activities on clinics to a more proportionate level and send a signal that it is indeed going to rein in the dangerous stem cell clinic industry for real,” says Paul Knoepfler, a … Divisions run deep over how to regulate stem cell clinics Stem cell research could lead to treatment breakthroughs Local Stem Cell Program to Launch Groundbreaking Clinical Trial on Parkinson's Patients |
